Lung Cancer News

The FDA approved FoundationOne CDx as a companion diagnostic to guide treatment selection for certain patients with non-small cell lung cancer.

The FDA approved nivolumab with platinum doublet chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer.

The FDA granted priority review to nivolumab for use with chemotherapy as neoadjuvant treatment of patients with resectable non-small cell lung cancer.

Rare Disease Day is Feb. 28.

Memorial Sloan Kettering Cancer Center placed a pause on a phase 1 clinical trial of ATA2271 — a chimeric antigen receptor T-cell therapy — after one patient treated with the investigational therapy died.

National lung cancer screening rates remained low and unchanged from 2019 to 2020, but rates significantly improved in 19 U.S. states despite the COVID-19 pandemic, according to data published in Chest.

The FDA should not make a regulatory decision on sintilimab for advanced lung cancer until additional study demonstrates applicability to U.S. patients, an advisory committee determined.

The U.S. Preventive Services Task Force’s 2021 guideline for lung cancer screening improved upon previous fixed-screening criteria and may reduce racial disparities in access, according to a study published in JAMA Oncology.

The addition of sugemalimab to first-line chemotherapy significantly prolonged OS among patients with stage IV non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

A blood test based on a four-marker protein panel combined with an independent risk prediction model that accounts for smoking history significantly improved patient selection for lung cancer screening, according to study results.